FDA advisory committee to review three cancer drugs this week

A Food and Drug Administration advisory committee is set to meet this week to discuss three cancer therapies. The Oncologic Drugs Advisory Committee is set to meet Wednesday to vote whether the benefits of Spectrum Pharmaceuticals Inc.’s SPPI, -1.85% treatment of patients with certain types of non-small cell lung cancer outweigh the risks. The same day the committee is also set to discuss Pepaxto, Oncopeptides AB’ ONCO, +1.72% investigational multiple myeloma treatment that received an accelerated approval in early 2021. A confirmatory trial did not produce a clinical benefit, the FDA said. On Thursday the FDA committee is then expected to examine Copiktra, the lymphocytic leukemia drug developed by the privately held Secura Bio Inc. This drug first received FDA approval in 2018; however, newer clinical data shows that the therapy may carry an increased risk of death compared to other medicines.